All News
Filter News
Found 175 articles
-
Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
6/22/2023
Seelos Therapeutics, Inc. today announced the close of enrollment of its registration directed study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD).
-
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
5/22/2023
Seelos Therapeutics, Inc. today announced that it will participate in two upcoming healthcare conferences.
-
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
5/15/2023
Seelos Therapeutics, Inc. today provided a clinical update and reported its financial results for the first quarter ended March 31, 2023.
-
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
5/5/2023
Seelos Therapeutics, Inc. announced that it has been selected to present a poster on SLS-009 at the American Society of Gene and Cell Therapy 26th Annual Meeting, to be held on May 16-20, 2023, in Los Angeles, California.
-
Top 2023 Neurodegenerative Readouts
4/17/2023
Clinical results for experimental treatments in Alzheimer’s, ALS and more are expected over the coming months. BioSpace highlights a few of the more highly anticipated datasets. -
Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
4/4/2023
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos") today announced it has dosed the first patient in an Expanded Access Program (EAP) for patients with ALS who do not qualify for existing clinical trials and that the EAP will be fully funded by a grant from the NINDS under the ACT for ALS.
-
Seelos Therapeutics Announces Business Update on its Key Programs
3/29/2023
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced a business update on its key programs.
-
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock - March 10, 2023
3/10/2023
Seelos Therapeutics, Inc. announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 12,059,298 shares of its common stock, pre-funded warrants exercisable for an aggregate of 9,340,702 shares of common stock and common warrants exercisable for an aggregate of 26,750,000 shares of common stock.
-
Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference
2/15/2023
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 43rd Annual Cowen Health Care Conference, to be held in Boston, Massachusetts on March 6-8th, 2023.
-
Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
2/13/2023
Seelos Therapeutics, Inc. (Nasdaq: SEEL) today announced the completion of enrollment of its registrational Phase II/III trial studying the investigational treatment SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) on the HEALEY ALS Platform Trial.
-
Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
2/10/2023
Seelos Therapeutics, Inc. (Nasdaq: SEEL) today announced that it has been selected to present a poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit in San Francisco, CA, February 21-23, 2023.
-
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
2/6/2023
Seelos Therapeutics, Inc. (Nasdaq: SEEL) today announced that it has dosed the first patients in an ethnobridging study in healthy adult Japanese and non-Asian subjects to compare the safety and pharmacokinetic profiles of SLS-002 (intranasal racemic ketamine).
-
Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
12/22/2022
Seelos Therapeutics, Inc. today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023.
-
Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
12/15/2022
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein).
-
Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
12/8/2022
Seelos Therapeutics, Inc. today released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15th from 1pm to 3pm ET.
-
Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022
11/23/2022
Seelos Therapeutics, Inc. today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET.
-
Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day
11/7/2022
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it will participate in the Guggenheim 4th Annual Immunology and Neurology Day, November 14th and 15th.
-
Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
10/25/2022
Seelos Therapeutics, Inc. today announced dosing of the first patient in a registrational phase II/III study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia focusing on participants with type3 (SCA3, also known as Machado-Joseph disease) and also announced that it will participate in the International Congress for Ataxia Research (ICAR) in Dallas, Texas November 1st – 4th, 2022.
-
Clene’s gold nanocrystal asset CNM-Au8 failed to hit the primary endpoint in the HEALEY ALS trial, but strong survival signals at six months warrant additional exploration in treating ALS.
-
Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program
9/30/2022
Seelos Therapeutics, Inc. today announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS.